Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03983096|
Recruitment Status : Not yet recruiting
First Posted : June 12, 2019
Last Update Posted : June 12, 2019
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1050 participants|
|Official Title:||Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer: an Real-world, Multicenter, Case Control Study.|
|Estimated Study Start Date :||June 15, 2019|
|Estimated Primary Completion Date :||February 1, 2020|
|Estimated Study Completion Date :||June 1, 2020|
Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
- Pathological complete remission (pCR) [ Time Frame: one year ]pCR was defned as no invasive cancer cells in any slices of the resected breast specimen.
- Disease-free survival （DFS） [ Time Frame: three years. ]The length of time after treatment during which no disease in found.
- Adverse event [ Time Frame: three years ]Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0.
- Breast conserving rate [ Time Frame: one year ]Breast conserving operation rate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03983096
|Contact: Jin Zhang, Pro.||86-022-23340123 ext email@example.com|
|Tianjin, China, 300000|
|Contact: Jin Zhang, Pro. 86-022-23340123 ext 2901 firstname.lastname@example.org|
|Sub-Investigator: Jin Zhang, Pro.|
|Study Chair:||Jin Zhang, Pro.||Tianjin Medical University Cancer Institute and Hospital|